Online inquiry

IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9905MR)

This product GTTS-WQ9905MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9905MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9052MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ12297MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ942MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ4823MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ4822MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ11713MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ14117MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ2658MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW